India, July 28 -- CervoMed Inc. (CRVO) has announced positive 32-week data from the Extension phase of its phase IIb RewinD-LB trial of oral investigational drug Neflamapimod for the treatment of dementia with Lewy bodies, and shares are up over 5% at $9.49 in premarket trading today.
Dementia with Lewy bodies (DLB) is a progressive disease where a protein known as alpha-synuclein builds up to form structures called Lewy bodies in the parts of the brain that control cognition, behaviour, and movements. Currently, there are no approved drugs for this condition.
According to the trial results, oral Neflamapimod continued to demonstrate slowing of disease progression and demonstrated an effect on a plasma marker of neurodegeneration in patie...